The infrastructure at SciLifeLab is a prerequisite for Key2Brain’s operations. The start-up company Key2Brain develops small antibody fragments which, when coupled with other proteins or drugs, can cross the blood-brain barrier and reach target molecules inside the brain. The company currently has projects in preclinical phase. The most mature project has successfully validated that the technology can provide optimized targeting of amyloid beta deposits in brain in disease models for Alzheimer’s disease, which can be used for diagnostics or therapeutics.
Industry case: SciLifeLab Infrastructure A Prerequisite for Key2Brain’s Development of Antibody Fragments for Brain Transport of Therapeutics
